Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Price Performance

Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00. The company has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24.

Get Genocea Biosciences alerts:

About Genocea Biosciences

(Get Free Report)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Read More

• Five stocks we like better than Genocea Biosciences
• Green Hydrogen Stocks Getting Ready to Deliver Big Gains
• Charles Schwab Gets The Rebound, Time to Buy?
• Is Ebix Inc a Phygital E-Commerce Contender or Pretender?
• 3 Mid-Cap Stocks with Expectations for High-Earnings Growth
• Can Lockheed Martin Fly To A New High In 2023?

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.